CClinicalTrials.gg
Status unknownNCT04712370Updated Jan 20, 2021

Conventional Caudal Block, Ultrasound Guided Caudal Block and Ultrasound Guided Erector Spinae Block for Pediatric Hip Surgery

An interventional study of Conventional caudal block and Ultrasound-guided caudal block in Conventional Caudal Block, Ultrasound Guided Caudal Block and Ultrasound Guided Erector Spinae Block, sponsored by Tanta University. Status unknown at 1 site in Egypt. Open to participants aged 4 Years to 12 Years. Per ClinicalTrials.gov, last updated 2021-01-20.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
4 Years to 12 Years
Sex
All
01

Study summary

This study will be conducted to compare the efficacy and safety of ultrasound guided erector spinae block , ultrasound guided caudal block and conventional caudal block for pain management after pediatric hip surgery.

02

Conditions studied

  • Conventional Caudal Block
  • Ultrasound Guided Caudal Block
  • Ultrasound Guided Erector Spinae Block
  • Pediatric Hip Surgery
03

In context

Lead sponsor

Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Both sex
  • ASA physical activity I, II
  • Age 4-12 years
  • Admitted for elective hip surgery.

Exclusion criteria

Exclusion Criteria:

  • Parents refusal
  • Children with severe systemic disease
  • ASA III or IV
  • Children with previous neurological or spinal anomaly, coagulation disorders
  • History of premature birth
  • Infection at the block injection site
  • History of allergy to local anesthetics
  • Bilateral hip surgery.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Active comparator
    Conventional caudal block

    Patients of this group will receive the conventional method (blind technique without ultrasound) of caudal block

    Procedure: Conventional caudal block

  • Experimental
    Ultrasound-guided caudal block

    Patients of this group will receive caudal block using ultrasound.

    Procedure: Ultrasound-guided caudal block

  • Experimental
    Ultrasound guided erector spinae plane Block

    Patients of this group will receive ultrasound guided erector spinae plane Block at the level of the transverse process of the second lumbar vertebrae(L2) .

    Procedure: Ultrasound guided erector spinae plane Block

Interventions

  • ProcedureConventional caudal block

    Patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected in the caudal epidural space) by the conventional method (blind technique without ultrasound).

  • ProcedureUltrasound-guided caudal block

    Using ultrasound, patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected in the caudal epidural space).

  • ProcedureUltrasound guided erector spinae plane Block

    Under ultrasound guidance, patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the transverse process of the second lumbar vertebrae(L2).

06

What researchers measure

Primary outcomes

  1. Degree of pain intensity

    To evaluate the pain scores by (FLACC) scale. (FLACC) scale will be assessed after surgery over 24 hours where (0 = Relaxed and comfortable, 1-3 = Mild discomfort, 4-6 = Moderate pain ,7-10 = Severe discomfort /pain)

    Time frame: First 24 hours postoperative

Secondary outcomes

  1. Changes in mean arterial blood pressure

    Mean arterial blood pressure will be recorded before block performance at T0, intraoperatively at 15 and 30 minutes, then every 30 min till the end of surgery and after surgery at T (0, 2, 4, 6, 12, 24 h).

    Time frame: Intraoperative and first 24 hours postoperative

  2. Changes in heart rate

    Heart rate will be recorded before block performance at T0, intraoperatively at 15 and 30 minutes, then every 30 min till the end of surgery and after surgery at T (0, 2, 4, 6, 12, 24 h).

    Time frame: Intraoperative and first 24 hours postoperative

  3. Amount of Analgesic required in the first day after surgery

    The total dose of intravenous (IV) acetaminophen 15 mg/kg if FLACC scores between 2 and 4 at the first 24 h after surgery, and total dose of tramadol 1 mg/kg (IV) in case of FLACC score \> 4.

    Time frame: First 24 hours postoperative

  4. Time to first rescue analgesic demand after surgery.

    measured from the end of surgery till patient require analgesia.

    Time frame: First 24 hours postoperative

  5. Success rate of block

    a successful block is defined as absence of significant changes in heart rate following surgical induction. Heart rate increase is not\>20% of the basal levels. If the increase is\>20%, the block is accepted as unsuccessful.

    Time frame: Intraoperative duration

  6. Duration of performing the block

    Block performing time is defined as the period between the insertion of the needle and termination of local anesthetic administration

    Time frame: Intraoperative duration

  7. Incidence of complications

    Hypotension, bradycardia, postoperative nausea, vomiting, urinary retention, prolonged motor block, pruritus and local anesthetic systemic toxicity (LAST).

    Time frame: Intraoperative and first 24 hours postoperative

07

Study locations

1 of 1 sites recruiting
  • Tanta University Hospitals
    Tanta, ElGharbiaa 31527, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be available upon reasonable request

Supporting information: Study protocol, Sap

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04712370
Lead sponsor
Tanta University
Responsible party
Eman Hamdy Abu-Shanab (Principal Investigator and Assistant lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Tanta University) — Principal investigator
First posted
Jan 15, 2021
Start date
Jan 16, 2021
Primary completion
Sep 1, 2021 (estimated)
Completion
Sep 10, 2021 (estimated)
Last update
Jan 20, 2021

Study contacts

Eman Hamdy Abu-Shanab, MSc
Contact
eman.hamdy@med.tanta.edu.eg
+201005518097

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion